Bacterial genome sequencing and drug discovery

Current Opinion in Biotechnology

Volumn 9, Issue 6, 1998, Pages 637-642

  Allsop, Aileen E ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL DNA;

BACTERIAL GENE; DRUG DEVELOPMENT; DRUG TARGETING; GENE SEQUENCE; GENOME; NONHUMAN; PRIORITY JOURNAL; REVIEW;

BACTERIA (MICROORGANISMS);

EID: 0032403024     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(98)80143-2     Document Type: Article

References (56)

1. Gold HS, Moellering RC. Antimicrobial-drug resistance. N Engl J Med. 335:1996;453-1445.
2. Levy SB. The Antibiotic Paradox: How Miracle Drugs are Destroying the Miracle. 1992;Plenum Press, New York and London.
3. Neu HC. The crisis in antibiotic resistance. Science. 257:1992;1064-1073.
4. Davies J. Inactivation of antibiotics and dissemination of resistance genes. Science. 264:1994;375-382.
5. Herrmann M, Weand M, Greshake B, von Eiff C, Proctor R, Scheld HH, Peters G. Left ventricular assist device infecton is associated with increased mortality but is not a contraindication to transplantation. Circulation. 95:1997;814-817.
6. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Micro Rev. 10:1997;720-741.
7. Gura T. Infections a cause of artery clogging plaques? Science. 281:1998;35.
8. Homberg A. Community-acquired pneumonia in adults. of special interest Curr Opin Infect Dis. 11:1988;47-151 Review of community-acquired pneumonia including diagnostics and the increasing understanding of the economic cost of this infection. Non-antibiotic therapies are also discussed.
9. The world Health Report. 1996;WHO Publications, Geneva.
10. Report of the ASM Task Force on Antibiotic Resistance. Supplement to Antimicrobial Agents and Chemotherapy. 1995.
11. Report of the House of Lords Select Committee on Science and Technology Resistance to antibiotics and other microbial agents. 1998;The Stationery Office, London, This report is written for the non-expert reader and gives a detailed view of the issues including 'misuse' of antibiotics in the UK. It also provides a very good overview of the US but not much data on the rest of the world.
12. of special interest Philips I, Young L. Clin Microbiol Infect. 3:1997; This supplement is an excellent update on the β-lactamases, including their clinical significance and an understanding of the efforts of the pharmaceutical industry to overcome susceptibility in the β-lactam antibiotics.
13. Jeljaszewicz J, Miynarczyk G, Miynarczyk A. Present and future problems of antibiotic resistance in Gram-positive cocci. Infection. 26:1988;1-5.
14. Dominiguez AM, Pallares R. Antibiotic resistance in respiratory pathogens. of special interest Curr Opin Infect Dis. 11:1998;139-145 This is an excellent world-wide review of respiratory pathogens and the growing problems of resistance.
15. Chopra I, Hodgson J, Metcalf B, Poste G. New approaches to the control of infections caused by antibiotic-resistance bacteria. JAMA. 275:1996;401-403.
16. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick J, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae. Science. 269:1995;496-512.
17. Blattner FR, Plunkett III, Bloch CA, Perna NT, Burland V, Riley M, Callodo-Vides J, Glasner JD, Rode CK, Mayhew GF, et al. The complete genome sequence of Escherichia coli K12. Science. 277:1997;1453-1462.
18. O'Brien C. Entire E. coli genome sequenced - at last. Nature. 385:1997;472.
19. Kunst F, Ogasawara N, Moszer I, Albetini AM, Alloni G, Azevedo V, Bertero MG, Bessiers P, Bolotin A, Borchert S, et al. The complete genome sequence of the Gram positive bacterium Bacillus subtilis. Nature. 390:1997;249-256.
20. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketcham KA, Klenk HP, Gill S, Dougherty BA, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 388:1997;539-547.
21. Cole ST, Brosch R, Patkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeir K, Gas S, Barry CE III, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 393:1998;537-544.
22. Salzberg S, Delcher A, Kasif S, White O. Microbial gene identification using interpolated Markov models. Nucleic Acids Res. 26:1998;544-548.
23. Dujon B. The yeast genome project: what did we learn? Trends Genet. 12:1996;263-270.
24. Winzeler EA, Davies RW. Functional analysis of the yeast genome. of special interest Curr Opin Genet Dev. 7:1997;771-776 A review of combinations of technologies and their impact on a total understanding of functional analysis resulting from the yeast genome project, including expression analysis, proteomics, subcellular localisation, protein - protein interactions and mutational analysis.
25. Oliver SG. Form gene to screen with yeast. of special interest Curr Opin Genet Dev. 7:1997;405-409 A review of the approaches taken in unravelling functionality in yeast, including novel strategies such as quantitative phenotypic analysis in combination with deletions, which seems a highly sensitive way for understanding complex effects and regulatory pathways, where simple on/off observations would be misleading. This paper also discusses the comparison with human medicine.
26. Basset EB Jr, Basrai MA, Connely C, Hyland KM, Kitagawa K, Mayer ML, Morrow DM, Page AM, Resto VA, Skibbens RV, Hieter P. Exploiting the complete yeast genome sequence. Curr Opin Genet Dev. 6:1996;763-766.
27. Thomas K. Yeasties and beasties: 7 years of genome sequencing. FEBS Lett. 396:1996;1-6.
28. Browne MJ, Gloger IS, Hodgson JE, Robinson JH. The importance of genome analysis to the drug discovery process. Mol Med Today. 1:1995;373-377.
29. Devine KM. The Bacillus subtilis genome project: aims and progress. Trends Biotechnol. 13:1995;210-216.
30. Hinton JC. The Escherichia coli genome sequence: the end of an era or the start of the FUN. of outstanding interest Mol Microbiol. 26:1997;417-422 The explanation of the pivotal role of E. coli as a model system in the investigation of bacterial gene function. Examination of why there are so many genes in this well studied species still not understood in terms of functionality. One explanation is the existence of more global regulatory systems that do not fit the current paradigms, or does E. coli have unrecognised biochemical versatilities? The possibility that many of these genes are truly cryptic seems unlikely, although not impossible.
31. Rosamond J. Two-hybrid analysis of protein - protein interactions in yeast. Methods Microbiol. 26:1997;256-267.
32. Fromont-Rancine M, Rain JC, Legrain P. Toward a functional analysis of the yeast genome through exhaustive two-hybrid screens. Nat Genet. 16:1987;277-282.
33. VanBogelen RA, Abshire KZ, Moldover B, Olson ER, Neidhart FC. Escherichia coli proteome analysis using the gene-protien database. of outstanding interest Electrophoresis. 18:1997;1243-1251 A thorough review of E. coli proteomics, the current technology and its potential in combination with genomics. Potential applications are discussed including the possibility of using proteomics to investigate physiology with particular reference to antibacterial drug hunting and the development of resistance. This technology is particularly suited to elucidation of global and complex mechanisms, such as triggering cidal processes or regulatory mutations.
34. Koonin EV. Genome sequences: genome sequence of a model prokaryote. of special interest Curr Biol. 7:1997;656-659 The author uses information and approaches associated with determination of evolutionary relationships, both molecular and whole genome, as a new way of postulating functionality. In particular, the importance of E. coli as a model systems is described.
35. Koonin EV, Mushegian AR, Galperin MY, Walker RD. Comparison of archaeal and bacterial genomes: computer analysis of protein sequences predicts novel functions and suggests a chimeric origin for the archaea. Mol Microbiol. 25:1997;619-637.
36. Tatusov RL, Altschul SF, Koonin EV. Detection of conserved segments in proteins: iterative scanning of sequence data bases with alignment blocks. Proc Natl Acad Sci USA. 91:1996;12091-12095.
37. Koonin EV, Galperin MY. Prokaryotic genomes: the emerging paradigm of genome-based microbiology. Curr Opin Genet Dev. 7:1997;757-763.
38. Strauss EJ, Falkow S. Microbial pathogenesis: genomics and beyond. of outstanding interest Science. 276:1997;707-712 This review is strong in realism and perspective and cautions in the dangers of reverting entirely to electronic microbiology for systems as complex as pathogenicity. It highlights, however, the potential that genomic information can have in 'giving clues' or a place to start from. This theoretical information in combination with new technologies, such as IVET, STM and DFI, is the most powerful strategy to date in understanding what makes a bacteria behave as a pathogen.
39. Camilli A, Mekalanos JJ. Use of recombinase gene fusions to identify Vibrio cholerae genes induces during infection. Mol Microbiol. 18:1995;671-683.
40. Heithoff DM, Conner CP, Mahan M. Dissecting the biology of a pathogen during infection. of special interest Trends Microbiol. 5:1997;509-513 This paper raises more questions than answers. The tools available need to express more complex questions than which genes are expressed during a pathogenic process, or even the co-ordination of that expression. What dictates tissue trophism, host specificity and disease manifestation.
41. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS. Expression monitoring by hybridisation to high-density oligonucleotide arrays. Nat Biotechnol. 14:1996;1675-1680.
42. Wodicka L, Dong H, Mittmann M, Ho HM, Lockhart DJ. Genomewide expression in Saccharomyces cerevissiae. of special interest Nat Biotechnol. 15:1997;1359-1367 Yeast expression arrays - 260,000 oligonucleotides made in situ by light-directed combinatorial chemistry. Expression compared with minimal to complete media, 90% of the gene expressed under both conditions, 50% at less than one copy per cell.
43. de Saizieu A, Certa U, Warrington J, Gray C, Keck W, Mous J. Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays. of outstanding interest Nat Biotechnol. 16:1998;45-48 A verification of transcript profiling technology in clinically relevant bacterial species, H. influenzac and S. pneumoniae. In the latter case, comparison of the data between this method and a more conventional approach. Northern blot analysis, were in good agreement. The problems associated with extraction of quality mRNA from bacteria seem to have been largely overcome as the sensitivity limits were between 1-5 copies per cell. Quantitative data were obtained and this technology can be adapted to look at the entire genome on a single chip.
44. Egerton M, Allsop AE, Boulnois GJ. Microbial genomics and the discovery of new antimicrobial therapies. of special interest Dixon GK, Coppoing LG, Livingstone D. Genomics - Commercial Opportunities From a Scientific Revolution. 1998;133-143 Bios Scientific Publishers, Oxford, This paper gives real examples of a commercial strategy using genomics for antimicrobial drug-hunting. Target selection and functional analysis technologies are described. Although the paper clearly represents early attempts to genomics in this way, simple, logical and pragmatic strategies are discussed.
45. Electrophoresis. 18:1997;1-29782.
46. Mann M, Wilm M. Electrospray mass spectrometry for protein characterisation. Trends Biochem Sci. 20:1995;219-224.
47. Gray CP, Keck W. The microbial postgenomic era: promises, problems and prospects. of outstanding interest Exp Opin Invest Drugs. 7:1998;145-148 Exploration of what new technologies might have to offer in the post-genomic era, with particular emphasis on understanding microbial physiology and the importance of complex systems in unravelling what is required in a successful antibiotic.
48. Russell CB, Thaler DS, Dahlquist FW. Chromosomal transformaton of Escherichia coli recD strains with linearised plasmids. J Bacteriol. 171:1989;2609-2613.
49. Ash C. Year of the genome. Trends Microbiol. 5:1997;135-139.
50. Devise KM, Wolfe K. Bacterial genomes: a TIGR in the tank. Trends Genet. 11:1995;429-431.
51. Quackerbush J, Adams MD, Fraser CM, Venter JC. Genome projects; from microbes to man, from sequence to function. Dixon GK, Coppoing LG, Livingstone D. Genomics - Commercial Opportunities From a Scientific Revolution. 1998;15-28 Bios Scientific Publishers, Oxford.
52. Finlay BB, Sansonetti P. Host - microbe interactions: bacteria the new age of infectious diseases. Curr Opin Microbiol. 1:1998;9-11.
53. Finlay BB, Falkow S. Common themes in microbial pathogenicity II. Mol Biol Rev. 61:1997;136-169.
54. Tang CM, Hood DW, Moxon R. Microbial genome sequencing and pathogenesis. Curr Opin Microbiol. 1:1998;12-16.
55. Tang CM, Hood DW, Moxon RE. Haemophilus influenzae: the impact of whole genome sequencing on microbiology. of special interest Trends Genet. 13:1997;399-404 Host - microbe interactions are complex and variable. The genome of H. influenzae provided the first comprehensive framework for rational analysis of such functions. Work on lipopolysaccharide in this organism and its role in virulence is not only of clinical relevance (vaccines etc.) but also provides a real examples of the power of this technology.
56. Thomas SM, Burke JF. Affymetrix: genes on chips. of special interest Exp Opin Ther Patents. 88:1998;503-508 At the time of going to press there are no publications giving details of what could be achieved in this area: however, the two World Wide Web sites (htp://www.biometrieux-vitek.com. htp//www.affymetrix.com) illustrate what has been already achieved in human diagnostic techniques and what is on the horizon for microbial diagnosis. The publication demonstrates the impact that 'genes on chips' are having in the diagnostic field as a whole.